Share on

Global Alzheimer's Disease Diagnostics And Therapeutics Market Size, Share, Trends, Growth Analysis Report - Segmented By Therapeutics, Diagnostics and Region – Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 2153
Pages: 178
Formats: report pdf report excel report power bi report ppt

Alzheimer's Disease Diagnostics and Therapeutics Market Size (2022 to 2027)

The global Alzheimer's disease therapeutics and diagnostics market is estimated to be growing at a CAGR of 4.67% from 2022 to 2027 and worth USD 14844 million by 2027 from USD 11815 million in 2022.

Alzheimer's disease (AD) is the most natural cause of progressive dementia in the elderly populace. There has been an exponential increase in the frequency of Alzheimer's disease cases globally, stressing the need to develop an effective treatment to cure it. Alzheimer's is a neurological disease affecting an individual's memory, thinking, and behavior. The traits usually worsen over time to the extent of the inability to perform daily tasks.

Alzheimer's disease (AD) is one of the most widespread dementia in the world. According to the facts and figures of the Alzheimer's Association, every 33 seconds, a new case with Alzheimer's disease occurs. At a very high stage, millions of patients are suffering. Eventually, the improvement in the technology regarding AD and neurodegenerative conditions is becoming significant. Unfortunately, 10-20% of AD diagnoses are inaccurate to overcome this hurdle. Alzheimer's disease is a degenerative and progressive disease that attacks the nerve cells, which results in the loss of memory, behavioral changes, and changes in thinking and language skills. There is fast growth in the number of people living with Alzheimer's disease, with around one individual in four diagnosed with this disease. 

MARKET DRIVERS:

The growth of the global Alzheimer's disease therapeutics and diagnostics market is mainly driven by factors such as the growing old age population, rising R&D investment, high frequency of Alzheimer's and neurodegenerative diseases, and improved life expectancy of the general population.

Factors such as the increasing elderly population, rising R&D spending, the high prevalence of Alzheimer's and neurodegenerative disorders, and the growing prevalence of chronic diseases such as dementia are propelling the market's growth rate. Furthermore, increasing the channels for drug development and investing in biomarkers also fuel the growth rate of the Alzheimer's disease therapeutics and diagnostics market. In addition, growing innovative diagnostics for early diagnosis, more specific drug development, and increased life expectancy in the general population drive the global Alzheimer's disease therapeutics and diagnostics market. According to the United Nation's Global Population Prospects 2019, by 2050, one in every six inhabitants will be over the age of 65, up from one in every eleven in 2019. Furthermore, the market is expected to expand due to an increase in the number of clinical studies relating to diagnosing and treating Alzheimer's disease.

The other factors anticipated to promote the growth of the AD therapeutics and diagnostics market are the increasing occurrence of chronic diseases like dementia, increasing channel drug development, venture into biomarkers for drug development, and increasing advanced diagnostics for early detection and more specific drug development. Presently, very few therapeutic options are on the market, and none offer a complete remedy for this condition. Hence, entry into the market would provide lucrative growth prospects to the market participants.

MARKET RESTRAINTS:

However, a shortage of surrogate indicators for drug discovery and production, inadequate testing resources, and long, unpredictable procedures are expected to hamper the growth rate of the global AD therapeutics and diagnostics market. With the rising number of people impacted, Alzheimer's disease is becoming a significant public health issue. Alzheimer's disease affects 5.3 million Americans and 35 million individuals globally. New treatments for diagnosing and treating Alzheimer's disease are desperately needed as the disease progresses worldwide. However, since the signs are mild and the anatomical changes in the brain and central nervous symptoms are not often evident by medical scans, early diagnosis of Alzheimer's disease (AD) is complex, and the early symptoms of Alzheimer's disease (AD) are often ignored. This restriction has severe consequences because late-stage diagnosis provides patients only symptomatic relief alternatives through drugs, reducing the potential advantage that may have been achieved through early medication and diagnosis. As a result, shortcomings in early-stage AD diagnosis restrict the global development of the AD diagnostics and therapeutics market.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2027

Base Year

2021

Forecast Period

2022 to 2027

Segments Analysed

By Therapeutics, Diagnostics, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

 

This research report on the global Alzheimer’s disease Diagnostics and Therapeutics Market is segmented and sub-segmented based on the Therapeutics, diagnostics, and region.

Alzheimer’s disease Diagnostics and Therapeutics Market – By Therapeutics:

  • Marketed Drugs
    • NMDA Receptor Antagonists
    • Cholinesterase Inhibitors
  • Pipeline Drugs

Due to a large user base, the marketed drugs segment will lead the global market based on therapeutics during the forecast period. Additionally, Cholinesterase inhibitors have the largest market share by size and are expected to witness a CAGR of 6.8% during the forecast period. Cholinesterase inhibitors have higher efficiency in the treatment of Alzheimer's. Most physicians and patients consider cholinergic drugs useful as the US FDA approves them. Several clinical trials are ongoing on cholinesterase inhibitors to increase drug efficacy and decrease adverse effects. Therefore, the cholinesterase inhibitor drug market will grow during the forecast period due to recent developments.

Alzheimer’s disease Diagnostics and Therapeutics Market – By Diagnostics:

  • Ct Scan
  • Electroencephalography
  • Lumbar Puncture Test
  • MRI
  • Positron Emission Tomography
  • Others

Among all the segments, the CT scan segment leads the global Alzheimer's disease (AD) Therapeutics and Diagnostics market. The absence of an alternative imaging tool for brain and neurological diagnostics is crucial for its large share.

Alzheimer’s disease Diagnostics and Therapeutics Market – By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Geographically, the North American Alzheimer's disease diagnostics and therapeutics market currently command a significant share of the global market. It is expected to sustain its stronghold in the future, owing to the growing prevalence of Alzheimer's disease and extensive technological developments in the region. The United States holds the largest share of the global Alzheimer's disease diagnostics and therapeutics market. The United States is the worldwide leader in Alzheimer's disease intervention and management. Numerous biopharmaceutical companies operate in America cumulatively, with 85 drugs for combating Alzheimer's disease in various pipeline stages. Hence, the market is expected to register a healthy CAGR over the forecast period.

With the growing aging population in developing regions of Asia Pacific, the APAC Alzheimer’s disease diagnostics and therapeutics market is expected to grow at the highest CAGR during the forecast period. Developing countries are expected to offer promising opportunities for this market. According to Alzheimer's disease International in 2015, 58% of dementia patients lived in developing countries, but by 2050 this will soar to 68%. The fastest aging population growth occurs in China, India, and their south Asian and western Pacific region. According to the World Alzheimer Report in 2015, regional estimations of dementia prevalence in people aged 60 years and over vary from 4.6% in Central Europe to 8.7% in North Africa and the Middle East. However, all other regional estimates fall between 5.6% and 7.6%.

The Europe Alzheimer’s disease diagnostics and therapeutics market is expected to be worth USD 3730.18 Million by 2027.

The Alzheimer’s disease diagnostics and therapeutics market in Latin America is predicted to showcase a CAGR of 4.43% from 2022 to 2027.

The Alzheimer’s disease diagnostics and therapeutics market in Middle East and Africa is estimated to value USD 776.22 by the end of 2022.

KEY MARKET PARTICIPANTS:

Some of the dominating companies in the Global Alzheimer's Disease Therapeutics and Diagnostics Market analyzed in this report are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare and Janssen Pharmaceuticals.

Please wait. . . . Your request is being processed

FAQ's

How big is the AD diagnostics and therapeutics market?

By 2027, the global Alzheimer's diagnostics and therapeutics market size is expected to value USD 14844 million.

Which region is dominating the AD diagnostics and therapeutics market?

In 2021, the North American region was the leader in the global AD diagnostics and therapeutics market.

Who are the major players in the AD diagnostics and therapeutics market?

Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare and Janssen Pharmaceuticals are the key players in the global AD diagnostics and therapeutics market.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: sales@marketdataforecast.com

Click for Request Sample